MassIVE MSV000086059

Complete Public PXD021276

eEF2K inhibition synergizes with Glutaminase and eIF4EBP1 inhibitors to suppress triple-negative breast cancer cell growth; impact on the proteome

Description

The eukaryotic elongation factor-2 kinase, eEF2K, restricts protein translation elongation, and was identified as a potential therapeutic target for diverse types of cancers including triple negative breast cancer (TNBC; PMID: 25330770). We have recently found that inhibition of eEF2K synergizes with depletion of eukaryotic translation initiation factor 4E-binding protein 1 (eIF4EBP1; 4E-BP1), a suppressor of eukaryotic protein translation initiation factor 4E (eIF4E), leading to effective growth suppression of TNBC cells in culture. We performed LC-MS/MS analysis following depletion of eEF2K and/or 4EBP in a TNBC cell line, Hs578t (YoungJun Ju & Eldad Zacksenhaus, manuscript in revisions). Depletion of these factors had overlapping effects on the proteome with the highest impact on Collagen containing extracellular matrix (e.g. COL1A1). The complete LC-MS/MS data sets (control vehicle; eEF2K-depletion, 4EBP1-depletion; combined eEF2k plus 4EBP1-depletion) are provided herein. [doi:10.25345/C5WQ97] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: eEF2K ; 4EBP1 ; translation initiation ; translation elongation ; cancer therapy ; triple negative breast cancer

Contact

Principal Investigators:
(in alphabetical order)
Eldad Zacksenhaus, UHN, Canada
YoungJun Ju, UHN, Canada
Submitting User: ureopa
Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files Browse Results
 
FTP Download Link (click to copy):

- Dataset Reanalyses


+ Dataset History


Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.